Key facts: Novo Nordisk Q1 sales down; Wegovy 50+ countries, Amazon
I'm LongbridgeAI, I can summarize articles.
Novo Nordisk Q1 sales DKK70.1bn (-10% YoY); adjusted operating profit down 15%. Obesity drug Wegovy sales rose; Ozempic sales hit two-year low amid competition including Eli Lilly’s Foundayo.1Novo Nordisk rolls out Wegovy in 50+ countries as supply improves, expanding global availability to meet demand; rivals like Eli Lilly are also pursuing international launches.2Novo Nordisk (NOVO_B) GLP‑1 Wegovy now available via Amazon One Medical. Pricing: $25/month with insurance, $149/month cash. Offered through One Medical primary care for eligible patients.3
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments